Table 3 Univariate and multivariate cox proportional hazards analysis of clinicopathological variables based on overall survival (OS) in the TCGA GBM training cohort and CGGA validation cohort
Variables | TCGA training cohort(n = 518) | CGGA validation cohort(n = 137) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |||||||||
HR | 95% CI | p.value | HR | 95% CI | p.value | HR | 95% CI | p.value | HR | 95% CI | p.value | |
Age | 1.032 | 1.025–1.040 | 1.98E-17 | 1.019 | 1.005–1.033 | 0.007 | 1.010 | 0.992–1.02 | 3.62E-01 |  |  |  |
Gender | 1.160 | 0.956–1.408 | 1.32E-01 |  |  |  | 1.220 | 0.84–1.78 | 2.94E-01 |  |  |  |
Surgery | 1.166 | 0.884–1.538 | 2.76E-01 |  |  |  | NA |  |  | NA |  |  |
KPS | 0.503 | 0.389–0.651 | 1.79E-07 | 0.981 | 0.669–1.439 | 0.922 | NA |  |  | NA |  |  |
TMZ chemotherapy | 0.578 | 0.476–0.703 | 3.82E-08 | 0.790 | 0.481–1.297 | 0.352 | 0.490 | 0.326–0.737 | 6.06E-04 | 0.494 | 0.328–0.743 | 7.15E-04 |
Radiotherapy | 0.281 | 0.220–0.359 | 1.58E-24 | 0.224 | 0.125–0.403 | 0.000 | 0.871 | 0.568–1.34 | 5.26E-01 |  |  |  |
Standard chemoradiation | 0.815 | 0.667–0.997 | 4.62E-02 | 1.017 | 0.696–1.486 | 0.932 | NA |  |  | NA |  |  |
G-CIMPstatus | 0.345 | 0.238–0.502 | 2.37E-08 | 0.271 | 0.035–2.101 | 0.211 | NA |  |  | NA |  |  |
TCGA Subtype | 0.926 | 0.855–1.004 | 6.08E-02 |  |  |  | NA |  |  | NA |  |  |
IDH mutation status | 0.362 | 0.226–0.577 | 2.03E-05 | 3.435 | 0.420–28.099 | 0.250 | 1.000 | 0.681–1.48 | 9.87E-01 |  |  |  |
MGMT promoter methylation status | 0.674 | 0.529–0.858 | 1.36E-03 | 0.869 | 0.625–1.209 | 0.404 | 0.898 | 0.628–1.28 | 5.53E-01 |  |  |  |
1p/19q codeletion status | NA |  |  | NA |  | NA | 0.783 | 0.363–1.69 | 5.32E-01 |  |  |  |
CDI high risk | 2.386 | 1.949–2.920 | 3.27E-17 | 2.850 | 1.981–4.100 | 0.000 | 1.520 | 1.06–2.17 | 2.31E-02 | 1.498 | 1.037–2.166 | 3.15E-02 |